Phase IB study of TNT009 in patients with Cold Agglutinin Disease

Trial Profile

Phase IB study of TNT009 in patients with Cold Agglutinin Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs BIVV-009 (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Dec 2017 According to a Bioverativ media release, primary and secondary outcome measures were achieved in the six patients with primary CAgD in the study.
    • 11 Dec 2017 According to a Bioverativ media release, six primary CAgD patients data was presented at the 59th Annual Meeting of the American Hematology Society.
    • 11 Dec 2017 Results (n=6) presented in a Bioverativ media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top